BioSpace News Archive

Sanofi's Distribution Center in Quebec, Canada

Earnings

Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.

October 25, 2024

·

3 min read

·

Tristan Manalac

2D illustration showing scientists' hands editing a DNA strand

Rare diseases

Intellia’s CRISPR Gene Editor Cuts Hereditary Angioedema Attacks by 81% in Phase II Study

Jefferies analyst Maury Raycroft said in a note to investors that Thursday’s mid-stage readout pointed to the “unprecedented” complete response rate of Intellia’s investigational in vivo gene editing therapy in the disorder.

October 25, 2024

·

2 min read

·

Tristan Manalac

Exterior view of the headquarters of the Centers for Disease Control and Prevention in Atlanta, Georgia

Vaccines

CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for adults aged 75 and older, and in seniors 60 to 74 years who are at risk of severe disease.

October 25, 2024

·

2 min read

·

Tristan Manalac

News

Vesalio Announces Clinical Study Initiative for the Recently Launched pVasc Thrombectomy System and Planned Attendance at TCT, VIVA, and VEITH Meetings

October 25, 2024

·

2 min read

News

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024